Observational studyEuropean journal of pediatrics2026
Expanded versus classical assessments for identifying mandate for lung ultrasound-guided surfactant therapy in preterm neonates (EXCLAIM-LUS): a retrospective comparative study.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung ultrasound (LUS) is increasingly used to guide surfactant therapy in preterm neonates with respiratory distress syndrome (RDS). To compare diagnostic performance of LUS scoring systems with various partitioning for predicting surfactant requirement in preterm neonates with RDS. Retrospective observational study. Preterm neonates (≤ 34 weeks) with RDS who underwent LUS within two hours of admission were included. Images were independently scored using four protocols: 6-area anterolateral (A/L), 6-area anterolateral-posterior (A/L/P), 10-area, and 12-area. All four scoring systems demonstrated good discrimination for surfactant requirement (AUC 0.800-0.831), with no statistically significant pairwise differences (all p ≥ 0.19). Decision curve analysis (DCA) confirmed positive net benefit for all protocols at threshold probabilities of 10-55%.
conclusionsAll four LUS scoring systems demonstrated comparable performance. Classical 6-area anterolateral protocol may be considered a pragmatic choice given its simplicity and comparable performance for routine LUS-guided surfactant therapy in preterm RDS. WHAT IS KNOWN: • LUS predicts surfactant need in preterm RDS (AUC 0.84-0.97). • Multiple scoring systems with varying zone counts exist but direct comparative evidence is lacking. WHAT IS NEW: • All four protocols (6-area anterolateral, 6-area Anterolateroposterior, 10-area eLUS, and 12-area) show comparable diagnostic performance (AUC 0.800-0.831) with overlapping decision curve net benefit. • The 6-area anterolateral protocol achieves equivalent utility with the lowest procedural burden.
Indexed as
Identifiers
42766165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.